Evidence map›Paper›PMID 39809264›Full record

ArticleCell reports. Medicine2025

High cellular plasticity state of medulloblastoma local recurrence and distant dissemination.

Hailong Liu, Jing Zhang, Ziwei Wang, Wei Wang, Dongming Han, Xuan Chen, Yu Su, Jiao Zhang, Craig Daniels, Olivier Saulnier and 33 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cell reports. Medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

43 authors.

Hailong LiuDepartment of Radiotherapy, Beijing Tiantan Hospital, Capital Medical University, Beijing 100070, China; Beijing Neurosurgical Institute, Beijing 100070, China; China National Clinical Research Center for Neurological Diseases, Beijing Tiantan Hospital, Capital Medical University, Beijing 100070, China; Chinese Institute for Medical Research, Beijing 100069, China.
Jing ZhangDepartment of Radiotherapy, Beijing Tiantan Hospital, Capital Medical University, Beijing 100070, China.
Ziwei WangBGI-Shenzhen, Shenzhen, Guangdong 518083, China.
Wei WangLaboratory of Tumor Immunology, Beijing Pediatric Research Institute, Beijing Children's Hospital, Capital Medical University, National Center for Children's Health, Beijing 100045, China.
Dongming HanBGI-Shenzhen, Shenzhen, Guangdong 518083, China; College of Life Sciences, University of Chinese Academy of Sciences, Beijing 100049, China.
Xuan ChenBGI-Shenzhen, Shenzhen, Guangdong 518083, China; College of Life Sciences, University of Chinese Academy of Sciences, Beijing 100049, China.
Yu SuSchool of Public Health, Capital Medical University, Beijing 100069, China.
Jiao ZhangCancer and Hematology Center, Texas Children's Hospital, Houston, TX 77002, USA; Department of Pediatrics-Hematology/Oncology and Neurosurgery, Baylor College of Medicine, Houston, TX 77002, USA; The Arthur and Sonia Labatt Brain Tumor Research Centre, The Hospital for Sick Children, Toronto, ON M5G 1, Canada; The Developmental and Stem Cell Biology Program, The Hospital for Sick Children, Toronto, ON M5G 1, Canada.
Craig DanielsCancer and Hematology Center, Texas Children's Hospital, Houston, TX 77002, USA; Department of Pediatrics-Hematology/Oncology and Neurosurgery, Baylor College of Medicine, Houston, TX 77002, USA; The Arthur and Sonia Labatt Brain Tumor Research Centre, The Hospital for Sick Children, Toronto, ON M5G 1, Canada; The Developmental and Stem Cell Biology Program, The Hospital for Sick Children, Toronto, ON M5G 1, Canada.
Olivier SaulnierGenomics and Development of Childhood Cancers Lab, Institute Curie, PSL University, 75005 Paris, France; Cancer Heterogeneity Instability and Plasticity, Institute Curie, PSL University, 75005 Paris, France.
Zeyuan John WangDepartments of Quantitative Pharmacology and Pharmacometrics (QP2), Merck & Co., Inc., West Point, PA 19486, USA.
Chunyu GuSanbo Brain Hospital Capital Medical University, Beijing 100093, China.
Fei LiuDepartment of Radiotherapy, Beijing Tiantan Hospital, Capital Medical University, Beijing 100070, China; Department of Neurosurgery, Beijing Tiantan Hospital, Capital Medical University, Beijing 100070, China.
Kaiwen DengDepartment of Radiotherapy, Beijing Tiantan Hospital, Capital Medical University, Beijing 100070, China; Department of Neurosurgery, Beijing Tiantan Hospital, Capital Medical University, Beijing 100070, China.
Dongyang WangDepartment of Neurosurgery, Beijing Tiantan Hospital, Capital Medical University, Beijing 100070, China.
Zhaoyang FengDepartment of Radiotherapy, Beijing Tiantan Hospital, Capital Medical University, Beijing 100070, China; Department of Neurosurgery, Beijing Tiantan Hospital, Capital Medical University, Beijing 100070, China.
Yahui ZhaoChina National Clinical Research Center for Neurological Diseases, Beijing Tiantan Hospital, Capital Medical University, Beijing 100070, China; Department of Neurosurgery, Beijing Tiantan Hospital, Capital Medical University, Beijing 100070, China.
Yifei JiangUniversity of Michigan-Shanghai Jiao Tong University Joint Institute, Shanghai Jiao Tong University, Shanghai 200240, China; Department of Biomedical Engineering, University of Michigan, Ann Arbor, MI 48109, USA.
Yu GaoProsper High School, Public School in Prosper, Prosper, TX 75078, USA.
Zijia LiuBGI-Shenzhen, Shenzhen, Guangdong 518083, China; College of Life Sciences, University of Chinese Academy of Sciences, Beijing 100049, China.
Mingxu MaDepartment of Radiotherapy, Beijing Tiantan Hospital, Capital Medical University, Beijing 100070, China.
Yanong LiDepartment of Radiotherapy, Beijing Tiantan Hospital, Capital Medical University, Beijing 100070, China.
Zitong ZhaoState Key Laboratory of Molecular Oncology, National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China.
Hongyu YuanState Key Laboratory of Molecular Oncology, National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China.
Youliang SunInstitute of Basic Medicine, School of Medicine, Tsinghua University Beijing 100084, China.
Yanfeng ShiChina National Clinical Research Center for Neurological Diseases, Beijing Tiantan Hospital, Capital Medical University, Beijing 100070, China.
Tao YangChina National GeneBank, BGI-Research, Shenzhen, Guangdong 518083, China.
Wenxing LiOE Biotech, Shanghai 201114, China.
Xueling QiSanbo Brain Hospital Capital Medical University, Beijing 100093, China.
Zejun DuanSanbo Brain Hospital Capital Medical University, Beijing 100093, China.
Junping ZhangSanbo Brain Hospital Capital Medical University, Beijing 100093, China.
Mingshan ZhangSanbo Brain Hospital Capital Medical University, Beijing 100093, China.
Chunjiang YuSanbo Brain Hospital Capital Medical University, Beijing 100093, China.
Wei JinThe First Medical Center, Chinese PLA General Hospital, Beijing 100039, China.
Xinguang YuThe First Medical Center, Chinese PLA General Hospital, Beijing 100039, China.
Yu TianSchool of Public Health, Capital Medical University, Beijing 100069, China.
Shuaicheng LiComputer Science Department, City University of Hong Kong, Kowloon, Hong Kong.
Chunde LiDepartment of Neurosurgery, Beijing Tiantan Hospital, Capital Medical University, Beijing 100070, China.
Michael D TaylorCancer and Hematology Center, Texas Children's Hospital, Houston, TX 77002, USA; Department of Pediatrics-Hematology/Oncology and Neurosurgery, Baylor College of Medicine, Houston, TX 77002, USA; The Arthur and Sonia Labatt Brain Tumor Research Centre, The Hospital for Sick Children, Toronto, ON M5G 1, Canada; The Developmental and Stem Cell Biology Program, The Hospital for Sick Children, Toronto, ON M5G 1, Canada.
Jiankang LiBGI-Shenzhen, Shenzhen, Guangdong 518083, China. Electronic address: lijiankang@genomics.cn.
Yong-Qiang LiuResearch Center of Chinese Herbal Resource Science and Engineering, School of Pharmaceutical Sciences, Guangzhou University of Chinese Medicine, Guangzhou, Guangdong 510006, China. Electronic address: liuyq@gzucm.edu.cn.
Xiaoguang QiuDepartment of Radiotherapy, Beijing Tiantan Hospital, Capital Medical University, Beijing 100070, China; Beijing Neurosurgical Institute, Beijing 100070, China. Electronic address: qiuxiaoguang@bjtth.org.
Tao JiangBeijing Neurosurgical Institute, Beijing 100070, China; China National Clinical Research Center for Neurological Diseases, Beijing Tiantan Hospital, Capital Medical University, Beijing 100070, China; Department of Neurosurgery, Beijing Tiantan Hospital, Capital Medical University, Beijing 100070, China. Electronic address: zacharytaojiang@163.com.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Medulloblastoma (MB), a heterogeneous pediatric brain tumor, poses challenges in the treatment of tumor recurrence and dissemination. To characterize cellular diversity and genetic features, we comprehensively analyzed single-cell/nucleus RNA sequencing (sc/snRNA-seq), single-nucleus assay for transposase-accessible chromatin sequencing (snATAC-seq), and spatial transcriptomics profiles and identified distinct cellular populations in SHH (sonic hedgehog) and Group_3 subgroups, with varying proportions in local recurrence or dissemination. Local recurrence showed higher cycling tumor cell enrichment, whereas disseminated lesions had a relatively notable presence of differentiated subsets. Chromosomal alteration evaluation revealed distinct genetic subclones during MB progression, such as chr7q gain and chr11 loss in Group_3 disseminations. A subpopulation termed "high cellular plasticity (HCP)" emerged during MB progression and was associated with increased dividing potential and chromatin accessibility, contributing to recurrence. Inhibiting HCP-associated markers, like protein tyrosine phosphatase receptor type Z1 (PTPRZ1), efficiently suppressed MB progression in preclinical models. These findings address critical gaps in understanding the cellular diversity, chromosomal alterations, and biological dynamics of recurrent MB, offering potential therapeutic insights.

Indexed as

Cell PlasticityCerebellar NeoplasmsMedulloblastomaNeoplasm Recurrence, LocalAnimalsCell Line, TumorChromatinGene Expression Regulation, NeoplasticHumansMiceSingle-Cell AnalysisChromatincellular plasticitymedulloblastomaPTPRZ1recurrence and dissemination

Identifiers

PMID39809264
PMCPMC11866544

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.